{'fraction_non_alphanumeric': 0.04307974335472044, 'fraction_numerical': 0.02474793767186068, 'mean_word_length': 5.100558659217877, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intravitreal Ranibizumab Injection for Idiopathic Choroidal Neovascularization in Children

Abstract We report two cases of idiopathic choroidal neovascularization (CNV) in pediatric patients treated with intravitreal ranibizumab injections (IVRs). A nine-year-old girl with decreased visual acuity in the left eye (20/100) was diagnosed with idiopathic CNV (case 1). The fluorescein angiography (FAG), indocyanine green angiography (ICG), and optical coherence tomography (OCT) revealed classic CNV. After two monthly IVRs, the visual acuity improved to 20/30 and stabilized without any adverse events. In case 2, a 10-year-old girl presented with decreased visual acuity (20/50) in the right eye. The OCT and FAG showed classic CNV. After one IVR, the visual acuity improved to 20/40 and the central foveal thickness was decreased. Visual acuity, FAG, ICG, OCT, serologic tests, and occurrence of ocular or systemic adverse events during follow-up were evaluated. During 14 and 12 months of follow-up for cases 1 and 2, respectively, no evidence of recurrence or adverse events were noted.